PCSK9 and Alzheimer disease: undertook a Mendelian randomisation study to explore the hypothesis that genetic variants in genes PCSK9 (and HMGCoA reductase) controlling LDL-cholesterol metabolism were associated with AD, dementia and with Parkinson’s disease (52).